Via Scoop.it – OphthalmologySecond Sight Wins 2011 World Technology Award. Argus II is Second Sight’s less invasive second generation implantable device intended to treat blind people suffering from degenerative diseases of the outer retina such as…Via www.marketwatch.com
Author: jfg@linkoph.com
Lucentis receive DME approval in EU
(Ophtalmology Times Europe) Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its therapy Lucentis for the treatment of patients with diabetic macular oedema (DME). Full Story ->